TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is headquartered in New York, New York.
| Revenue (TTM) | $799.54M |
| Gross Profit (TTM) | $658.60M |
| EBITDA | $136.45M |
| Operating Margin | 9.02% |
| Return on Equity | 100.30% |
| Return on Assets | 7.28% |
| Revenue/Share (TTM) | $5.61 |
| Book Value | $4.11 |
| Price-to-Book | 12.37 |
| Price-to-Sales (TTM) | 9.44 |
| EV/Revenue | 9.6 |
| EV/EBITDA | 55.04 |
| Quarterly Earnings Growth (YoY) | -70.60% |
| Quarterly Revenue Growth (YoY) | 70.30% |
| Shares Outstanding | $153.08M |
| Float | $135.24M |
| % Insiders | 7.47% |
| % Institutions | 74.20% |
Volatility is currently contracting
908 Devices outlined its strategy to focus exclusively on handheld chemical and drug detection technologies for public safety and defense markets, following the divestiture of its life-sciences business line about 15 months ago.
TG Therapeutics, Inc. remains a Buy as BRIUMVI's momentum supports a durable, growing multiple sclerosis franchise. TGTX's Q2 saw BRIUMVI revenue surge 64% YoY to $228 million, prompting 2026 guidance to $950 million, though net income was impacted by manufacturing investments. Subcutaneous BRIUMVI, with Phase 3 data expected late 2026 or early 2027, could expand the addressable market and drive future gross margin tailwinds.
TG Therapeutics misses Q2 earnings estimates, but surging Briumvi demand lifts revenues y/y and prompts higher 2026 revenue guidance. Stock falls.
TG Therapeutics, Inc. (TGTX) Q2 2026 Earnings Call Transcript
The headline numbers for TG Therapeutics (TGTX) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
TG Therapeutics NASDAQ: TGTX reported second-quarter 2026 revenue of $240 million and raised its full-year sales outlook for BRIUMVI, its treatment for relapsing multiple sclerosis, as the company cited record new patient starts, continued prescriber expansion and higher-than-expected treatment persistence.
TG Therapeutics (TGTX) came out with quarterly earnings of $0.05 per share, missing the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.17 per share a year ago.
Second quarter 2026 total global revenue of approximately $240 million, including BRIUMVI U.S. net product revenue of approximately $228 million Raises full year 2026 total global revenue target to approximately $950 million and raises full year 2026 BRIUMVI U.S. net product revenue target to approximately $890 - 905 million Conference call to be held today, Monday, August 3, 2026, at 8:30 AM ET NEW YORK, Aug. 03, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the second quarter of 2026, along with recent company developments and provided an update on 2026 financial guidance. Michael S.
NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Monday, August 3, 2026, at 8:30 AM ET to discuss results for the second quarter 2026 and to provide a business outlook for the remainder of 2026. Michael S.
TG Therapeutics (TGTX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on TGTX and any ticker you trade — then tracks every position and per-strategy win rate.
